RTP Mobile Logo

Friday, December 13, 2019, San Antonio, Texas, 7:30 PM – 9:00 PM

Data + Perspectives: Clinical Investigators Explore the Current and Future Management of HER2-Positive Breast Cancer

Part 3 of a 3-Part CME Satellite Symposia Series

Event Details

San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

7:30 PM – 9:00 PM — Educational Dinner Meeting

Meeting Room
Grand Ballroom G-M (Third Floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Adam M Brufsky, MD, PhD
Professor of Medicine
Associate Director for Translational Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Division Chief
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Lisa A Carey, MD
Richardson and Marilyn Jacobs Preyer
Distinguished Professor for Breast Cancer Research
Chief, Division of Hematology and Oncology
North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Sara Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Santa Monica, California

Martine J Piccart-Gebhart, MD, PhD
Scientific Director
Jules Bordet Institute
Université Libre de Bruxelles
Brussels, Belgium

Neil Love, MD
Research To Practice
Miami, Florida


MODULE 1: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy

  • Long-term efficacy outcomes with the use of anthracycline- and nonanthracycline-based neoadjuvant systemic therapy platforms; prognosis of patients who experience a pathologic complete response compared to those who do not
  • Design, eligibility criteria and patient accrual for the Phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for patients with HER2-positive primary BC and residual disease after preoperative therapy
  • Key efficacy and safety results from the KATHERINE trial; clinical and research implications of the FDA approval of adjuvant T-DM1 for HER2-positive localized BC
  • Indications for the use of adjuvant pertuzumab for patients receiving it as part of neoadjuvant therapy
  • Emerging genomic assays and markers (eg, plasma microRNA levels) to help identify patients with HER2-positive disease more likely to respond to neoadjuvant systemic therapy

MODULE 2: Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC

  • Selection of postoperative systemic therapy for patients with HER2-positive localized BC who have not received prior neoadjuvant systemic therapy
  • Available Phase III data with, FDA approval of and patient selection for pertuzumab as a component of adjuvant chemobiologic therapy
  • Emerging results from the randomized Phase II ATEMPT trial comparing adjuvant T-DM1 to paclitaxel/trastuzumab for Stage I HER2-positive BC
  • FDA approval of neratinib as extended-adjuvant therapy; patient selection and clinical factors (eg, ER/PR status, tumor size, nodal status) guiding its use in practice
  • Recognition, prevention and management of gastrointestinal toxicities associated with neratinib; role of concomitant loperamide and budesonide
  • Ongoing and planned clinical trials for patients with localized HER2-positive BC

MODULE 3: Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC)

  • Clinical factors affecting the selection of first-line therapy for patients with HER2-positive mBC (eg, prior HER2-directed therapy, symptomatology, performance status, disease-free interval, sites of metastases)
  • Treatment for patients with HER2-positive mBC experiencing disease progression after receiving pertuzumab or T-DM1 as a component of neoadjuvant or adjuvant therapy; role of rechallenge with these agents
  • Effect of prior neratinib exposure on the sequence and selection of therapy for patients with HER2-positive mBC
  • Comparative efficacy and safety of T-DM1 versus other approved therapies for patients with HER2-positive mBC, including those with CNS metastases
  • Available efficacy and safety findings from the Phase III NALA study of neratinib/capecitabine for patients with HER2-positive mBC; current nonresearch role of neratinib in mBC

MODULE 4: Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC

  • Mechanism of action of and early activity and safety data with the selective HER2 inhibitor tucatinib
  • Emerging findings from the pivotal Phase II HER2CLIMB trial of trastuzumab/capecitabine with or without tucatinib for patients with HER2-positive locally advanced or metastatic BC
  • Structural makeup of and early efficacy and safety with the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mBC
  • FDA breakthrough therapy designation for trastuzumab deruxtecan and emerging data from the Phase II DESTINY-Breast01 trial
  • Biologic rationale for and ongoing investigation of the use of trastuzumab deruxtecan in patients with HER2-low advanced BC
  • Results from the Phase III SOPHIA trial comparing margetuximab/chemotherapy to trastuzumab/chemotherapy for HER2-positive mBC
  • Early activity with and ongoing evaluation of other novel agents and strategies under development for patients with HER2-positive mBC

CE Information

Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing early breast cancer, and integrate this information into current treatment decision-making.
  • Apply emerging research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive early breast cancer who have previously received neoadjuvant treatment.
  • Evaluate published research data to guide the selection and duration of adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing early breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and emerging targeted treatments.
  • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other relevant factors.
  • Recognize the side effects associated with existing and recently approved systemic therapies for HER2-positive breast cancer, and develop strategies to prevent or ameliorate toxicities to support quality of life and continuation of treatment.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for metastatic HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, Puma Biotechnology Inc and Seattle Genetics.


San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (Third Floor)

The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center.



Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. If you are interested in attending, please visit our onsite registration desk, which will open at 7:00 PM on Friday, December 13. Our onsite registration desk will be located outside Grand Ballroom G-M on the third floor of the Marriott Rivercenter hotel (101 Bowie Street, San Antonio, TX 78205), which is within 1.5 blocks of the Henry B González Convention Center. 

We will accept onsite registration until reaching the meeting room capacity. Please note, onsite registration does not guarantee participation in the session or meal service, and seating will be prioritized for clinicians in practice.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153 or +1 (305) 377-2828.


This educational session has been approved by SABCS as an official adjunct CME satellite symposium, and registration for this event is independent of registration for SABCS.